NCT00121992View on ClinicalTrials.gov

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

1,060

Participants

Timeline

Start Date

July 31, 1999

Primary Completion Date

December 2, 2010

Study Completion Date

March 6, 2013

Conditions
Breast Neoplasms
Interventions
DRUG

Docetaxel

DRUG

5-fluorouracil

DRUG

Doxorubicin

DRUG

Cyclophosphamide

Trial Locations (1)

28700

Spanish Breast Cancer Research Group, San Sebastián de los Reyes

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Spanish Breast Cancer Research Group

OTHER